



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

### ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**Ms:** 3515

**Title:** The serrated pathway in colorectal carcinogenesis

**Reviewer code:** 00503561

**Science editor:** x.x.song@wjgnet.com

**Date sent for review:** 2013-05-03 21:39

**Date reviewed:** 2013-05-14 17:39

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

### COMMENTS

#### COMMENTS TO AUTHORS:

In table 2, provide the population (Asians, Caucasians, or Japanese, Korean, etc.). Small typos are found In the last line of page 3: Chron > Crohn Rectosigmoide > rectosigmoid

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**Ms:** 3515

**Title:** The serrated pathway in colorectal carcinogenesis

**Reviewer code:** 00058688

**Science editor:** x.x.song@wjgnet.com

**Date sent for review:** 2013-05-03 21:39

**Date reviewed:** 2013-05-15 22:20

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS

### COMMENTS TO AUTHORS:

Minor revision: Typos: 1, Introduction - 3rd paragraph - 5th line - Crohn instead of Chron 2, Putative genetic pathways in serrated carcinomas - 5th paragraph - 10th line - 43% of TSA instead of 43%ofTSA 3, Putative genetic pathways in serrated carcinomas - 5th paragraph - 11th line - CpG island instead of CpGisland 4, Table 2 - Kim et al - GCHP / MSI-H - na instead of Na Questions for the authors: 1, The authors write that the serrated carcinomas that originate from traditional serrated adenomas generally are MSS or MSI-L and those that originate from a sessile serrated adenoma are MSI. However, in Figure 2 TSA are MSI-H. Why do you thinkg that TSA are MSI-H when Kim et al proved that only 3% of TSA are MSI-H? 2, The authors write that in GCHP, KRAS mutations are likely the most important genetic alteration. Why do you think that when Sandmeier et al and Kim et al both proved that BRAF mutation occurs more often in GCHPs? 3, In tables 1 and 2, please provide the population.

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**Ms:** 3515

**Title:** The serrated pathway in colorectal carcinogenesis

**Reviewer code:** 00058688

**Science editor:** x.x.song@wjgnet.com

**Date sent for review:** 2013-05-03 21:39

**Date reviewed:** 2013-05-15 22:20

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS

### COMMENTS TO AUTHORS:

Minor revision: Typos: 1, Introduction - 3rd paragraph - 5th line - Crohn instead of Chron 2, Putative genetic pathways in serrated carcinomas - 5th paragraph - 10th line - 43% of TSA instead of 43%ofTSA 3, Putative genetic pathways in serrated carcinomas - 5th paragraph - 11th line - CpG island instead of CpGisland 4, Table 2 - Kim et al - GCHP / MSI-H - na instead of Na Questions for the authors: 1, The authors write that the serrated carcinomas that originate from traditional serrated adenomas generally are MSS or MSI-L and those that originate from a sessile serrated adenoma are MSI. However, in Figure 2 TSA are MSI-H. Why do you thinkg that TSA are MSI-H when Kim et al proved that only 3% of TSA are MSI-H? 2, The authors write that in GCHP, KRAS mutations are likely the most important genetic alteration. Why do you think that when Sandmeier et al and Kim et al both proved that BRAF mutation occurs more often in GCHPs? 3, In tables 1 and 2, please provide the population.